EMEA-001373-PIP01-12-M04
Key facts
| Invented name |
Mysimba
|
| Active substance |
|
| Therapeutic area |
Other
|
| Decision number |
P/0390/2021
|
| PIP number |
EMEA-001373-PIP01-12-M04
|
| Pharmaceutical form(s) |
Prolonged-release tablet
|
| Condition(s) / indication(s) |
Treatment of obesity
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Orexigen Therapeutics Ireland Limited
E-mail: eu-regulatory@orexigen.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|